Metastatic PRAME-Expressing Juvenile Spitzoid Melanoma on the Buttock

Muto, Yusuke; Fujimura, Taku; Kambayashi, Yahiko; Ohuchi, Kentaro; Amagai, Ryo; Hashimoto, Akira; Aiba, Setsuya

doi:10.1159/000510261

Cited by 3 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preferentially expressed antigen in melanoma (PRAME) was originally discovered as an antigen associated with melanoma in autologous T‐cells from a patient with metastatic disease 5 . Recent studies have supported diffuse melanocytic nuclear PRAME expression as a sensitive and specific immunohistochemical marker for melanoma 6‐12 . PRAME is known to act, in part, via inhibition of retinoic acid signaling, conferring a growth and survival advantage to melanoma cells 13 .…”

Section: Introductionmentioning

confidence: 99%

Preferentially expressed antigen in melanoma and p16 expression in acral melanocytic neoplasms

et al. 2021

View full text Add to dashboard Cite

Acral melanocytic neoplasms often pose diagnostic difficulty. Preferentially expressed antigen in melanoma (PRAME) expression and loss of p16 expression have diagnostic utility in melanocytic tumors. We examined PRAME and p16 expression in 30 acral melanocytic neoplasms (n = 11 nevi; n = 2 dysplastic nevi; n = 7 Spitz nevi; n = 10 acral melanomas). PRAME was scored as % positive nuclei: negative = 0%; 1% to 25% = 1+; 25% to 50% = 2+; 50% to 75% = 3+, or positive: 75% to 100% = 4+. p16 expression was defined as retained (homogeneous or checkerboard) or lost (complete or partial/regionally). PRAME expression was negative in all benign, dysplastic, and Spitz nevi. Conversely, all acral melanomas were diffusely (4+) positive for PRAME expression. p16 expression was retained in all benign acral nevi (8/11 homogeneous, 3/11 checkerboard), completely lost in one dysplastic nevus, and retained in all acral Spitz nevi (3/7 homogeneous, 4/7 checkerboard). p16 was retained in five of 10 acral melanomas (3/10 homogeneous; 2/10 checkerboard), and negative in five of 10 acral melanomas (absent in 3/10, partially lost in 2/10). Our data suggest that 4+ PRAME expression is highly sensitive and specific in the setting of acral melanomas and is a more predictive diagnostic tool compared with p16 immunohistochemistry.

show abstract

Section: Introductionmentioning

confidence: 99%

Preferentially expressed antigen in melanoma and p16 expression in acral melanocytic neoplasms

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In this scenario, rising attention is being devoted to this marker, and new studies are being conducted in an attempt to increase experiences, report results, and find safer answers [ 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 ].…”

Section: Discussionmentioning

confidence: 99%

Preferentially Expressed Antigen in Melanoma (PRAME) and Human Malignant Melanoma: A Retrospective Study

Cazzato

Mangialardi

Falcicchio

et al. 2022

Genes

View full text Add to dashboard Cite

Background: Preferentially expressed antigen in melanoma (PRAME) is a cancer testis antigen (CTA) identified in 1997 through analysis of the specificity of tumor-reactive T-cell clones derived from a patient with metastatic cutaneous melanoma. Although at first it seemed even more specific, various studies have shown that PRAME can also be expressed in the context of atypical lesions that do not correspond solely to the definition of malignant melanoma. Methods: A systematic review of English articles was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Results: 126 records were identified in the literature search, of which 9 were duplicates. After screening for eligibility and inclusion criteria, 53 publications were included. Conclusions: The advent of a new marker such as PRAME is surely a step forward not only in the diagnostic approach, but also in the immunotherapeutic approach to MM. However, various studies have shown that PRAME can also be expressed in the context of atypical lesions apart from MM and, for this reason, the diagnostic sensitivity and specificity (hence accuracy) are clearly lower. Further studies with larger case series will be necessary to understand better what possibilities are offered in terms of diagnostic reliability by PRAME.

show abstract

“… Immunohistochemical stain for PRAME (preferential expressed antigen in melanoma): (Reproduced from “Metastatic PRAME Expressing Juvenile Spitzoid Melanoma on the Buttock” by Muto et al, published by Karger Publishers under the Creative Commons CC-BY-NC 4.0 license, © The Author(s) [ 133 ]. ( A ) Histology of primary lesion, ( B ) Histologic findings of a metastatic lymph node, ( C ) PRAME immunohistochemical staining of the primary tumor ( D ) PRAME immunohistochemical staining of a metastatic lymph node [ 133 ]. …”

Section: Figurementioning

confidence: 99%

Melanoma Biomarkers and Their Potential Application for In Vivo Diagnostic Imaging Modalities

Hessler

Jalilian

et al. 2020

IJMS

View full text Add to dashboard Cite

Melanoma is the deadliest form of skin cancer and remains a diagnostic challenge in the dermatology clinic. Several non-invasive imaging techniques have been developed to identify melanoma. The signal source in each of these modalities is based on the alteration of physical characteristics of the tissue from healthy/benign to melanoma. However, as these characteristics are not always sufficiently specific, the current imaging techniques are not adequate for use in the clinical setting. A more robust way of melanoma diagnosis is to “stain” or selectively target the suspect tissue with a melanoma biomarker attached to a contrast enhancer of one imaging modality. Here, we categorize and review known melanoma diagnostic biomarkers with the goal of guiding skin imaging experts to design an appropriate diagnostic tool for differentiating between melanoma and benign lesions with a high specificity and sensitivity.

show abstract

Metastatic PRAME-Expressing Juvenile Spitzoid Melanoma on the Buttock

Cited by 3 publications

References 9 publications

Preferentially expressed antigen in melanoma and p16 expression in acral melanocytic neoplasms

Preferentially expressed antigen in melanoma and p16 expression in acral melanocytic neoplasms

Preferentially Expressed Antigen in Melanoma (PRAME) and Human Malignant Melanoma: A Retrospective Study

Melanoma Biomarkers and Their Potential Application for In Vivo Diagnostic Imaging Modalities

Contact Info

Product

Resources

About